Psych Capital PLC - Admission to trading on AQSE
RNS Number : 2230O
Psych Capital PLC
09 June 2022
 

Psych Capital Plc

("Psych Capital" or the "Company")

 

Admission to trading on AQSE

 

Psych Capital Plc, the psychedelic healthcare incubation and investment company, that operates the leading industry  data, insights, and networking platform, PSYCH, with over 20,000+ subscribers and over 3,000 delegates to previous events, is pleased to announce that admission of its shares to trading on the Aquis Stock Exchange Growth Market ("AQSE Growth Market") will commence at 8.00a.m. today under the TIDM "PSY" and the ISIN number GB00BL6CJQ54.

 

The Company's Admission Document is available at the Company's website: https://psych.capital

 

Key Highlights

·    The Company currently has exposure to key segments of the medical psychedelic sector through strategic acquisitions and investments, including:

·    Clinical research in connection with the development of psychedelic medicines used to treat addiction;

·    Data collection in relation to developments in the psychedelic sector (including, the legal framework, commerce and science); and

·    Media and communications platform for the medical psychedelic industry

·    The Company intends to identify, fund and support the building of future companies across three core pillars: therapeutic treatments, drug development, and data/artificial intelligence

·    The Company will leverage its portfolio of brands, and network of experts, to identify early-stage opportunities in the medical psychedelic industry

·    The Psych Platform is a global B2B resource for networking, intelligence, and insights, servicing the industry through publications, newsletters and engaging events

·    PSYCH Symposium events generate strong revenue through sponsorship and ticket sales.

 

Compelling Investment Proposition

Psych Capital is a publicly listed incubation and investment firm that deploys early stage capital whilst building or supporting new companies in Europe's psychedelic science and healthcare industry.

 

PSYCH is a data and intelligence platform for the psychedelic science and healthcare industry. It has quickly become the industry's leading resource - powered by trustworthy data, independent analysis and engaging events that attract a highly influential audience of policy makers, scientists and investors.

 

Market Opportunity 

The nascent psychedelics' space is quickly being harnessed by a growing base of institutional investors seeking to establish and scale businesses in a landscape showing scientific and commercial promise.

 

·    Psych's offering aims to capitalise on the following market dynamics:

 

·    Numerous companies are currently creating training plans for psychedelic therapists, including the MIND Foundation and COMPASS Pathway;

·    The United Nations (UN) Convention on Psychotropic Substances framework for the international control of psychotropic substances lists: Psilocybin, MDMA, DMT and LSD as Schedule I substances, the category indicating the least harm with medical application;

·    Ketamine is on the WHO list of essential medicines;

·    Psilocybin therapy is expected to be a key driver in societal education and a contributor to wider reforms across America;

·    MDMA-assisted therapy can take a strong market share from 2024;

·    Capital invested in psychedelic companies is over US$2 billion; and

·    The current value of medical businesses surpasses US$10 billion. For example, ATAI Life Sciences' initial public offering (IPO) last year made it the most valuable publicly-traded business in the sector, currently valued at US$595 million.

 

Placing

The Company has raised gross proceeds of £810k from the issue and allotment of 16,200,000 Placing Shares.

 

The Company intends to apply the net proceeds raised from the fundraising activities to support its general working capital requirements and to develop its existing business, whilst certain funds may be applied to enable the Company to make further acquisitions.

 

Total voting rights 

Following Admission, the total number of Ordinary Shares in issue will be 290,033,335 each with equal voting rights. The Company does not hold any rights in treasury. The total voting rights figure can be used by Shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest in, or a change of their interest in, the Company under the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority.

 

William Potts, Chief Investment Officer and Co-Founder of Psych Capital, commented: "We're the first pure play Psychedelic company to list on a UK stock market at an inflection point for the industry as global interest moves towards the UK due to the leading science and companies here. We believe our IPO is a milestone for the whole psychedelic industry in the UK.    

 

"With an escalating global mental health crisis, there's a significant opportunity for innovation to cater to unmet needs and improve patient outcomes worldwide. Encouraged by breakthrough trials and science of psychedelic-assisted therapy, our mission is to support a new wave of innovators who are well positioned to challenge the status-quo and revolutionise how society deals with mental health conditions."

 

The Directors of the Company accept responsibility for the contents of this announcement. 

 

For further information, please contact:

 

Psych Capital Plc


Stephen Murphy, Executive Director


William Potts, Chief Investment Officer

 

info@PSYCH.capital or via Walbrook PR Ltd psych@walbrookpr.com

 


AQSE Growth Market Corporate Adviser


Peterhouse Capital Limited

Tel: +44 (0) 207 469 0930

Guy Miller / Mark Anwyl


 


Walbrook PR Ltd (Media & Investor Relations)

Tel: +44 (0)20 7933 8780 or psych@walbrookpr.com

Nick Rome / Tom Cooper

Mob: +44 (0) 7748 325 236 / +44 (0) 7971 221 972

 

 

About Psych Capital Plc

Psych Capital Plc identifies, funds and aims to support the building of British and European companies across three core pillars: therapeutic treatments, drug development, and data/AI. Its mission is to support a new wave of innovators who are well positioned to challenge the status-quo and revolutionise how society deals with mental health conditions.

 

Through a network of analysts with deep industry knowledge and capital markets expertise, Psych Capital is focussed on developing a rigorously selected portfolio of industry leading companies at the intersection of psychedelic medicine and technology.

 

The Psych Platform is a business-to-business media and content platform for the psychedelic science and healthcare industry, and it operates the website, https://psych.global/. The Psych Platform is a global B2B resource for networking, intelligence and insights, servicing the industry through publications, newsletters and engaging events. The Psych Platform has amassed a significant global B2B audience, with over 20,000 subscribers to the platform.

 

As a business-to-business media and content platform, the Psych Platform also produces the PSYCH Symposium, a premium Live Event series.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NEXBLGDLIXGDGDI ]]>